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. Preamble
.1. Need for developing case deﬁnitions and guidelines for data
ollection, analysis, and presentation for congenital anomalies as
n adverse event following immunization
Congenital anomalies, also commonly referred to as birth
efects, congenital disorders, congenital malformations, or con-
enital abnormalities, are conditions of prenatal origin that are
resent at birth, potentially impacting an infant’s health, develop-
ent and/or survival. We  will use the term congenital anomalies in
his report. Congenital anomalies encompass a wide array of struc-
ural and functional abnormalities that can occur in isolation (i.e.,
ingle defect) or as a group of defects (i.e., multiple defects). Multi-
le defects may  occur as part of well-described associations, such as
he non-random co-occurrence of Vertebral anomalies, Anal atre-
ia, Cardiac defects, Tracheoesophageal ﬁstula, and/or Esophageal
tresia, Renal and Radial anomalies, and Limb defects (VACTERL)
1].
Congenital anomalies vary substantially in severity. Some
ongenital anomalies are associated with spontaneous abortion,
tillbirth, or death in the early postnatal period. Global deaths due
o congenital anomalies decreased from 750.6 thousand in 1990 to
32.1 thousand in 2013, with respective age-standardized death
ates of 11.0 and 8.7 per 100,000 [2]. Subtypes of fatal congen-
tal anomalies (with estimated number of global deaths in 2013
n thousands) are congenital heart anomalies (323.4), neural tube
efects (68.9), Down’s syndrome (36.4), and chromosomal unbal-
nced rearrangements (17.3) [2]. Other congenital anomalies may
ave little impact on survival. Anomalies which affect an infant’s
ife expectancy, health status, physical or social functioning may
e described as “major” anomalies. In contrast, “minor” anomalies
re those with little or no impact on health or short-term or long-
erm function [3]. We have chosen to focus on major anomalies for
his case deﬁnition due to their impact on public health and pre-
xisting structure for surveillance and reporting by large national
nd international organizations.
The causes of congenital anomalies are wide-ranging, with
any anomalies remaining of undetermined etiology. Structural
nomalies are often due to errors in embryogenesis occurring at
ritical periods of fetal development. Critical exposure periods
uring pregnancy can vary by organ system or type of anomaly.
owever, ﬁrst trimester (gestational age 1–13 weeks) is generally
onsidered the highest risk period. Medications, infectious agents,
nd environmental toxins have all been implicated as teratogens;
llicit drugs and other maternal exposures can also disrupt fetal
evelopment and increase the risk for one or more congenital
bnormalities [1]. Some structural and many functional defects are
ttributed to underlying genetic defects or chromosomal abnor-
alities. These defects may  be due to one or both parents being
enetic carriers, one or both parents sharing the disease state, or the
ccurrence of de novo mutations [4]. The timing of clinical recogni-
ion of major anomalies varies both by type of defect and by access
o health care.
To date, multiple studies have investigated congenital anomaly
utcomes following maternal vaccination, for both recommended
nd inadvertent vaccination.
.1.1. Vaccinations routinely recommended during pregnancy
.1.1.1. Inﬂuenza vaccine, including seasonal and pandemic vac-
ines. Many countries routinely recommend that pregnant women
eceive inﬂuenza vaccine at any time during pregnancy [5,6].
016hus, studies evaluating the potential for these vaccines to impact
mbryogenesis or risks for congenital anomalies are of criti-
al importance. Maternal immunization during pregnancy with
nactivated inﬂuenza vaccine is associated with a brief increase in (2016) 
maternal inﬂammatory biomarkers [7,8]. At the time of publication,
there was no data to support an association between the maternal
inﬂammatory response to vaccination and fetal development and
risk for congenital anomalies.
As of March 2014, congenital anomaly data from more than 4000
pregnant women who received different types of adjuvanted and
non-adjuvanted inﬂuenza vaccination during the ﬁrst trimester,
and over 19,000 during any trimester, were published [9–20]
and comprehensively reviewed [21]. Of individual studies, the
largest that included ﬁrst trimester exposures reported pregnancy
outcomes for 323 woman immunized with adjuvanted or non-
adjuvanted A(H1N1)v2009 inﬂuenza vaccines and 1329 control
subjects. The rate of major malformations did not vary between
the two cohorts (all trimesters: OR 0.87; 95% conﬁdence inter-
val [CI] 0.38, 1.77; preconception and ﬁrst trimester exposure: OR
0.79; 95% CI 0.13, 2.64) [16]. The review authors concluded that
maternal inﬂuenza vaccination is not associated with an increased
risk of congenital malformations. However, statistical imprecision,
and clinical and methodological heterogeneity of included studies
made it impossible to totally exclude harm [21]. A 2014 Cochrane
systematic review combining ﬁve studies in a meta-analysis also
found inﬂuenza immunization during pregnancy was not associ-
ated with a higher risk of congenital anomalies, pooled estimate
OR 1.06 (95% CI, 0.90, 1.25) [11–13,16,17,22].
Since March 2014 there have been at least three retrospec-
tive studies published investigating congenital anomaly outcomes
following monovalent inﬂuenza A (H1N1) vaccines [23–25]. The
largest of the three studies was  conducted in Lombardy, Italy, dur-
ing the pandemic period (October 1, 2009–September 30, 2010)
and included 6246 pregnant women immunized with a MF59
adjuvanted pandemic A (H1N1) vaccine [24]. Pregnancies were
excluded if either chromosomal aberrations or congenital viral
infections were reported in the birth registry. Cases were identiﬁed
with ICD-9 coding and retained according to EUROCAT guidelines.
Unmatched analysis identiﬁed 284/6246 (4.5%) cases of congenital
malformations in the immunized cohort and 3246/79,925 (4.1%) in
the unimmunized cohort, OR 1.13 (95% CI, 0.99, 1.28), and propen-
sity matched OR 1.14 (95% CI, 0.99, 1.31) [24]. Rates and estimates
were also available for speciﬁc anomalies.
1.1.1.2. Tetanus diphtheria, acellular pertussis vaccines (Tdap). Many
countries recommend administration of the acellular pertussis vac-
cine during the third trimester of pregnancy [26,27]. One placebo
randomized controlled trial, conducted from 2008 to 2012, exam-
ined infant congenital anomaly outcomes following maternal Tdap
administration during pregnancy. Between 30 and 32 weeks gesta-
tion, 33 women  received the Tdap vaccine and 15 received a placebo
vaccine, with crossover immunization postpartum. In the vacci-
nated cohort one infant had a congenital anomaly, as compared to
two infants with congenital anomalies in the control group [28]. To
date, two  retrospective observational studies of Tdap administra-
tion during pregnancy have been published in the United States;
both suggest there is not a signiﬁcantly increased risk of major
congenital anomalies in infants born to mothers who were vacci-
nated during pregnancy [29,30]. The remaining evidence regarding
the safety of pertussis containing vaccines is derived from passive
surveillance [31].
Maternal and neonatal tetanus remain problematic in geo-
graphic areas where childbirth occurs under conditions that do not
meet minimum standards of hygiene and immunization coverage
of the population is low. In these regions, women  with inadequate
immunization history are recommended to receive two doses of
34 6015–6026tetanus toxoid (TT) containing vaccine as early as possible during
pregnancy [32]. Between 1959 and 1965 a large prospective study
in the United States was  conducted that included 337 mother and
child pairs evaluated for TT vaccine exposure before 20 weeks
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cine 34estation. The authors estimated a standardized relative risk (SRR)
f 1.19 (95% CI, 0.70, 1.87) for any anomaly following tetanus
accination during pregnancy [33]. In more recent case-control
tudies, increased risks of congenital anomalies following maternal
T vaccination were not observed [34,35]. In one of these studies,
0 women (55% of vaccinated women) were exposed during
he ﬁrst three gestational months [34]. In the other, timing of
accination during pregnancy was not reported [35].
.1.2. Vaccinations inadvertently administered during pregnancy
Many vaccines are routinely administered to women of
eproductive age, increasing the opportunities for inadvertent vac-
ination during pregnancy. Thus, continued monitoring of birth
utcomes among women inadvertently exposed during pregnancy
emains a priority.
.1.2.1. Live virus vaccines (rubella, measles, mumps, oral poliovirus,
ellow fever, and varicella). Inadvertent maternal vaccination with a
ive virus vaccine is associated with replication of the vaccine virus
nd likely a more robust maternal inﬂammatory response than
hat observed for inactivated vaccines. However, of greater con-
ern, maternal infections with rubella, varicella, cytomegalovirus
nd other viruses, during critical periods of fetal development,
re associated with speciﬁc groupings of congenital anomalies or
yndromes [36]. Thus, there is a theoretical risk for inadvertent
aternal vaccination with a live virus vaccine to result in a fetal
nfection and subsequently increase risk for one or more congenital
nomalies.
A review of the inadvertent administration of live vaccines
monovalent or combined rubella, oral poliomyelitis virus, and
ellow fever vaccines) to pregnant females suggests no evidence
f adverse pregnancy outcomes [37]. The incidence of congenital
ubella syndrome (CRS) following inadvertent rubella vaccina-
ion of pregnant women has been evaluated in several countries
n Europe, the United States, Canada, Iran and Latin America.
mong more than 3500 susceptible women inadvertently vacci-
ated against rubella shortly before or in the ﬁrst trimester of
regnancy, no cases of CRS were reported [38–45].
No speciﬁc studies have been conducted on pregnancy out-
omes following inadvertent measles or mumps  vaccination.
assive surveillance of vaccine exposures prior to conception and
uring pregnancy has not indicated an increased risk of congen-
tal malformation or spontaneous abortion [46], but there is not
ufﬁcient information to exclude such a risk.
Oral poliovirus vaccine (OPV), containing live attenuated
oliovirus types 1, 2, and 3, has been widely used since the 1960s to
rotect pregnant women and neonates against poliomyelitis. The
ossible development of viremia following immunization and a
ew cases suggestive of vaccine-associated anomalies including an
nexplained report about fatal spinal cord neuronal damage fol-
owing maternal immunization in an immune mother have been
ocumented [47]. However, no population-based controlled stud-
es are available to conﬁrm the signiﬁcance of these individual
eports. In response to a poliovirus epidemic in Finland during 1985,
PV was given to 94% of the entire population, including pregnant
omen. There was no observed increase in the rates of growth
etardation, perinatal deaths, prematurity or congenital anoma-
ies in the infants exposed to OPV in utero in comparison with the
xpected rates [48].
Yellow fever vaccination has been documented in several hun-
red pregnant women. The risks of adverse outcome of pregnancy
nd childbirth appear to be similar to those in the general popula-
M. DeSilva et al. / Vacion [49,50].
Data from a U.S. registry of pregnant women who inadver-
ently received varicella vaccine either 3 months before, or at any
ime during, pregnancy, showed that, among the 587 prospectivelyenrolled women  (including 131 live births to women known to be
varicella-zoster virus-seronegative), there was no evidence of con-
genital varicella syndrome [51]. The rate of occurrence of congenital
anomalies from prospective reports in the registry was similar to
reported rates in the general U.S. population (3.2%) and the anoma-
lies showed no speciﬁc pattern or target organ.
1.1.2.2. Human papillomavirus (HPV) vaccine. To date, data on the
safety of the bivalent HPV (2vHPV), 4-Valent HPV (4vHPV), and
9-Valent HPV (9vHPV) vaccines administered inadvertently dur-
ing pregnancy are based on the pre-licensure clinical studies and
post-marketing surveillance studies. The latter have been mostly
passive, voluntary reporting registry surveillance, which extended
for the 4vHPV vaccine until 2012 and is ongoing for the 9vHPV
vaccine since licensure by the US FDA in 2015. As of today, there
are no data to suggest an increased risk of congenital malforma-
tions following exposure to HPV vaccines during pregnancy, but
overall numbers of cases have been low, potentially limiting sta-
tistical power and precluding the ability to deﬁnitively rule out
associations of the HPV vaccines with speciﬁc anomalies.
A pooled analysis of 42 pre-licensure clinical studies of the
2vHPV vaccine that included 479 pregnancies in which date of last
menstrual period occurred between 30 days prior to 45 days after
vaccination did not ﬁnd an increased risk of congenital anomalies,
when compared to 414 controls with similar timing of vaccination
(1.7 vs. 2.2%) [52]. Similarly, a pooled analysis of ﬁve pre-licensure
clinical studies of the 4vHPV vaccine did not ﬁnd a signiﬁcant dif-
ference in the rate of congenital anomalies when comparing 2008
pregnant women  receiving vaccination with 2029 pregnant women
receiving placebo (2.0 vs. 1.5%, p = 0.20) [53].
Post-marketing data on the safety of HPV vaccines adminis-
tered during pregnancy include manufacturer-sponsored registries
of the 2vHPV and 4vHPV vaccines, reports on the 4vHPV vac-
cine to the Vaccine Adverse Event Reporting System (VAERS), a
passive surveillance system in the United States, and an obser-
vational cohort study of the 2vHPV vaccine conducted using data
from the United Kingdom. Voluntary reporting is known for under-
reporting of congenital anomalies if not detected at birth, and
over-reporting bias for anomalies is common with the use of ret-
rospective reports. The manufacturer-supported registries have
therefore only used prospective inadvertent vaccine exposure
reports for the calculation of the congenital anomaly rates [54]. The
manufacturer-sponsored registries observed overall rates of major
congenital malformations that were consistent with the back-
ground rates in the populations [5 of 189 live born infants (2.6%)
and 37 of 1527 live born infants (2.4%), respectively in the 2vHPV
and 4vHPV registries] [55,56]. Additionally, in an analysis of 4vHPV
vaccine reports submitted between June 2006 and December 2013
to VAERS, only two major congenital malformations were reported
out of all infants born to 147 women  who received 4vHPV dur-
ing pregnancy [57]. Published data from a formal epidemiologic
study on the safety of HPV vaccines during pregnancy in the post-
licensure setting come from an observational cohort study in the
Clinical Practice Research Datalink; no difference was observed in
the percentage of congenital malformations resulting from preg-
nancies in which pregnancy initiation occurred between 30 days
prior to 45 days after 2vHPV vaccination (7 of 119 pregnancies,
5.9%) vs. 120 days to 18 months after vaccination (23 of 350 preg-
nancies, 6.6%) [58]. Nakalembe et al., conducted a systematic review
of 14 studies that evaluated vaccine safety following administration
of 2vHPV and 4vHPV vaccines in low and middle income countries
[58]. Of the 14 studies, four included information related to preg-
 (2016) 6015–6026 6017nancy outcomes; no difference was found between groups in these
4 studies.
Results from the multi-national, double-blind, randomized
phase IIb/III trial of the 9vHPV in 14,215 women have recently
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een published. Pregnancy was reported in 1192 participants in
he 9vHPV group and 1129 participants in the 4vHPV group [59].
regnancy outcome data was available for 85% of pregnancies. Con-
enital anomalies were reported in a total of 32 infants and 9 fetuses
nd rates did not differ between groups (20 in the 9vHPV group and
1 in the 4vHPV group). Among pregnancies with an estimated date
f conception within 30 days prior to or after 4vHPV or 9vHPV vac-
ine administration, (representing 8% of pregnancies with known
utcome), no congenital anomalies were reported [59].
.1.2.3. Meningococcal vaccine. Evidence on the safety of adminis-
ration of meningococcal vaccination during pregnancy is scarce. A
ystematic review conducted in 2012 identiﬁed 6 studies evaluat-
ng the safety of Meningococcal Polysaccharide Vaccine (MPSV) in
regnancy [60]. None of the included studies suggested any adverse
utcomes, including birth defects, for infants born to mothers who
eceived MPSV during pregnancy. However, the total study popula-
ion included 335 women which may  be too small to evaluate rare
utcomes such as congenital anomalies.
The safety information on meningococcal conjugate vaccines
MCV) is derived from passive surveillance [61,62]. These data do
ot suggest harmful events on birth outcomes, including congeni-
al anomalies, when MCV  is administrated to pregnant women. To
ate, no data are available on the safety of new Meningococcal B
accines when administered during pregnancy.
.1.3. Background summary
The evidence on potential risks for congenital anomalies follow-
ng maternal immunization is mostly reassuring. However, studies
o date have been limited by insufﬁcient sample sizes, varied deﬁ-
itions for outcomes, and use of non-biologically feasible exposure
indows. One or more congenital anomalies are estimated to occur
n 3% of pregnancies [63]. However, speciﬁc isolated defects gener-
lly occur at rates of 1 per 10,000 to 1 per 100,000 births [64]. Given
M. DeSilva et al. / Va018he variability in types and causes of birth defects, future studies
f maternal vaccine safety will need much larger sample sizes or
lternative approaches (e.g., case-control studies) to detect risks for
ongenital anomalies, both isolated defects and groups of defects.
able 1
ist of organizations focused on research related to congenital anomalies, speciﬁc term an
Organization Congenital anomaly
terminology
Deﬁnition
National Institute of Child
Health and Human
Developmenta
Birth defects Birth defects are s
disability, intellec
be  fatal, especially
WHOb Congenital Anomaly Structural or func
prenatally, at birth
National Birth Defects
Prevention Networkc
Birth defects Major anomaly – 
adverse effect on 
Minor anomaly – 
not  seriously affec
Metropolitan Atlanta
Congenital Defects Programd
Birth defects Major structural o
deformation, or d
known clinical syn
development, or f
March of Dimese Birth defects Health conditions
body. Birth defect
works.
WHO/CDC/International
Clearinghouse for Birth
Defects Monitoring Systemsf
Birth defects Wide range of abn
prenatal origin.
a https://www.nichd.nih.gov/health/topics/birthdefects/Pages/default.aspx.
b http://www.who.int/mediacentre/factsheets/fs370/en/.
c http://www.nbdpn.org/docs/SGSC - Ch3 Case Deﬁnition - ﬁnal draft 3-24-15.pdf.
d http://www.cdc.gov/ncbddd/birthdefects/macdp.html.
e http://www.marchofdimes.org/.
f http://www.icbdsr.org/page.asp?p=9895&l=1.1.1.4. Established deﬁnitions
Subtle differences exist among the various deﬁnitions for con-
genital anomalies used by organizations specializing in congenital
anomalies and development. The National Institute of Child Health
and Human Development (NICHD), Metropolitan Atlanta Congen-
ital Defects Program (MACDP), National Birth Defects Prevention
Network (NBDPN), and the March of Dimes use the term “birth
defects” to describe congenital anomalies. NBDPN subcategorizes
birth defects into major and minor anomalies. The deﬁnitions used
by these organizations focus on both structural and functional
abnormalities that are present at birth that have signiﬁcant health
consequences. Please see Table 1 for a complete list of these orga-
nizations and the deﬁnitions used.
There is no uniformly accepted deﬁnition of congenital anoma-
lies, or more speciﬁcally, of congenital anomalies following
maternal immunization. This is a missed opportunity, as data com-
parability across trials or surveillance systems would improve
data interpretation and promote the scientiﬁc understanding of
the event. Through the provision of standardized case deﬁnitions
and guidelines, this document is intended to improve reliability
and comparability of data collected from immunized patients and
controls in clinical trials, as well as provide a framework for consis-
tently monitoring the safety of vaccines currently recommended
during pregnancy or available to women  of reproductive age. Such
data can be used in the assessment of whether or to what extent
a vaccine administered during pregnancy may  increase a woman’s
risk for having a live birth or fetal demise with one or more con-
genital anomalies. The case deﬁnitions and guidelines are intended
to be applicable in diverse geographic, administrative, and cultural
regions, adaptable to both high and low resource settings.
1.2. Methods for the development of the case deﬁnition and
guidelines for data collection, analysis, and presentation for
congenital anomalies as an adverse events following
immunization
 (2016) 4 6015–6026Following the process described in the overview paper [65]
as well as on the Brighton Collaboration Website (http://www.
brightoncollaboration.org/internet/en/index/process.html), the
d deﬁnitions used by each organization.
tructural or functional abnormalities present at birth that can cause physical
tual and developmental disability (IDD), and other health problems. Some may
 if not detected and treated early.
tional anomalies that occur during intrauterine life and can be identiﬁed
 or later in life.
congenital abnormality that requires medical or surgical treatment, has a serious
health and development, or has signiﬁcant cosmetic impact
congenital abnormality that does not require medical or surgical treatment, does
t health and development, and does not have signiﬁcant cosmetic impact
r genetic birth defects as conditions that (1) result from a malformation,
isruption in one or more parts of the body, a chromosomal abnormality, or a
drome; (2) are present at birth; and (3) have a serious, adverse effect on health,
unctional ability.
 present at birth that change the shape or function of one or more parts of the
s can cause problems in overall health, how the body develops or how the body
ormalities of body structure or function that are present at birth and are of
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cine 3righton Collaboration Congenital Anomalies Working Group was
ormed in 2015 and included members with backgrounds in clinical
edicine, research, public health and industry. The composition
f the working and reference group as well as results of the web-
ased survey completed by the reference group with subsequent
iscussions in the working group can be viewed at: http://www.
rightoncollaboration.org/internet/en/index/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
ines, a literature search was performed using Medline and Embase,
ncluding the terms Pregnant Women/OR Pregnancy/OR preg-
ant.ti,ab. OR pregnancy.ti,ab. AND Vaccines/OR Vaccination/OR
inadvertent ADJ3 vaccin*).ti,ab. OR (vaccin* ADJ3 pregnan*).ti,ab.
ND exp congenital abnormalities/OR birth defect*.ti,ab. OR con-
enital abnormalit*.ti,ab. OR congenital malformation*.ti,ab. OR
risk ADJ2 (f?etus OR infant* OR bab* OR biolog*)).ti,ab. The search
as limited to English language articles and resulted in the identi-
cation of >400 references. All abstracts were screened for possible
eports of congenital anomalies following immunization. Over 60
rticles with potentially relevant material were reviewed in more
etail, in order to identify studies using case deﬁnitions or, in their
bsence, providing clinical descriptions of the case material. This
eview resulted in a detailed summary of >60 articles, including
nformation on the study type, the vaccine, the diagnostic criteria or
ase deﬁnition put forth, the time interval since time of immuniza-
ion, and any other symptoms. Multiple general medical, pediatric
nd infectious disease text books were also searched.
The literature search yielded publications in which terminology
as inconsistent. An inventory comprising 6 relevant case deﬁ-
itions (Table 1) of congenital anomalies was made available to
orking group members.
.3. Rationale for selected decisions about the case deﬁnition of
ongenital anomalies as an adverse event following immunization
The group of conditions comprising “Congenital Anomalies” is
uite diverse. Our workgroup suggests that isolated congenital
nomalies can be stratiﬁed into three broad categories:
. External structural defects (e.g., cleft lip or gastroschisis)
. Internal structural defects (e.g., congenital cardiac defects or
intestinal atresias)
. Functional defects (e.g., galactosemia or Gaucher’s disease).
As previously mentioned, congenital anomalies might occur in
solation (single defect) or as a group of defects (multiple defects)
hich are often part of well-described associations (e.g., VACTERL).
n addition, there may  be overlap between categories for certain
ongenital anomalies. For example, chromosomal defects are often
ssociated with major internal structural defects.
For external structural, internal structural and functional
efects, the timing of clinical recognition varies by defect type
nd by access to health care. For example, in high resource
ettings, many structural congenital anomalies are diagnosed pre-
atally through ultrasound or other advanced imaging. Similarly,
n high resource settings, functional anomalies may  be diagnosed
hrough genetic screening following amniocentesis, chorionic villi
ampling, or maternal blood testing. If not detected prenatally,
ncluding in low resource settings, external structural defects are
sually evident at the time of birth. In contrast, it is common in
oth high and low resource settings for both internal structural
efects and functional defects to be diagnosed in the days, weeks,
r months following birth. The diverse range of congenital anoma-
M. DeSilva et al. / Vacies and their varied clinical presentation highlights the difﬁculty of
ssigning a single classiﬁcation system. In addition, major congen-
tal anomalies may  result in spontaneous abortion, stillbirth or an
lective therapeutic abortion, and therefore may  not be capturedif data collection is limited to live births. It is therefore empha-
sized, that the possibility of congenital anomalies should always be
considered when evaluating etiology for a spontaneous abortion or
stillbirth.
Within the deﬁnition context, we have assigned four levels of
diagnostic certainty to each category listed above. For each cate-
gory, a ﬁfth level is included to indicate that the event does not
meet the case deﬁnition for congenital anomalies. The case deﬁ-
nition has been formulated such that the Level One deﬁnition is
highly speciﬁc for the condition. As maximum speciﬁcity normally
implies a loss of sensitivity, additional diagnostic levels have been
included in the deﬁnition, offering a stepwise increase of sensitivity
from Level One down to Level Three, while retaining an acceptable
level of speciﬁcity at all levels. In this way it is hoped that all possi-
ble cases of congenital anomalies can be captured. The diagnostic
levels must not be misunderstood as reﬂecting different grades of
clinical severity. They instead reﬂect diagnostic certainty for the
presence of a particular congenital anomaly.
When evaluating the possibility of a congenital anomaly, con-
ditions and syndromes due to either known maternal conditions
(e.g., pre-eclampsia or gestational diabetes) or prematurity (e.g.,
patent foramen ovale or patent ductus arteriosus) should be dis-
tinguished from standalone congenital anomalies not related to
known causes.
It needs to be re-emphasized that the grading of deﬁnition lev-
els is entirely about diagnostic certainty, not clinical severity of an
event. Thus, clinically severe anomalies may  appropriately be clas-
siﬁed as Level Two or Three rather than Level One if there is no
evidence of a speciﬁc conﬁrmatory test. However, detailed infor-
mation about the severity of the event should always be recorded,
as speciﬁed by the data collection guidelines.
The meaning of “Sudden Onset” and “Rapid progression” in the
context of congenital anomalies is not applicable as the anomaly or
predisposition to develop the anomaly is, by deﬁnition, present at
birth.
We have attempted to provide adequate diagnostic speciﬁcity
without being overly restrictive in order to create deﬁnitions that
are applicable in both high and low resource settings. With regards
to speciﬁc pathology, radiology, or laboratory ﬁndings necessary to
meet the case deﬁnition, these ﬁndings will vary based on the spe-
ciﬁc congenital anomaly being evaluated. The current deﬁnitions
refer to broad categories of anomalies; more comprehensive deﬁ-
nitions for speciﬁc congenital anomalies, (e.g., Tetralogy of Fallot)
including well-deﬁned associations or combinations of anomalies
(e.g., CHARGE) have been developed elsewhere and are beyond the
scope of this working group [3]. We  have included appendices of
speciﬁc major congenital anomalies listed by groups across the
globe conducting birth defects surveillance. In addition, our clas-
siﬁcation is speciﬁc to major anomalies, affecting survival, physical
or social functioning. Classiﬁcation of minor anomalies, occur-
ring as isolated or multiple defects, is beyond the scope of this
paper.
A treatment response or its failure, is not in itself diagnostic,
and may  depend on variables like clinical status, time to treatment,
and other clinical parameters. For congenital anomalies, treatment
is often a surgical intervention. In the absence of standard pathol-
ogy, radiology, or laboratory ﬁndings, documentation of speciﬁc
treatments (e.g., surgical reports) may  be used in evaluating case
status. Our deﬁnitions account for the possibility of an early surgi-
cal correction or, for functional anomalies, a deﬁnitive treatment
(e.g., stem cell transplant or dietary restrictions).
 (2016) 4 6015–6026 60191.3.1. Timing of vaccination during pregnancy
It is widely recognized that ﬁrst trimester is the most critical
period for teratogen exposure during pregnancy with regards to
subsequent effects on fetal development [66]. However, there is
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ariability in the timing of fetal development by gestational week
67]. In addition, more precise timing of embryogenesis depends
n the organ or anomaly of interest. With this in mind, the tim-
ng of maternal vaccine exposure needs to be both biologically
lausible and consistent among studies in order for associations
etween congenital anomalies and maternal vaccination to pro-
ide reliable information. In order to allow for wider windows
f teratogen exposure, account for potential errors in assigning a
ate of conception and gestational age, and focus on exposures
uring the most plausible time period for development of congen-
tal anomalies, we recommend that maternal vaccination from 30
ays prior to conception to 20 weeks gestational age be included
n the case deﬁnition. We  understand that some will choose to
nclude maternal vaccination outside this time period. However,
f a true risk during the biologically plausible exposure window
xists, inclusion of exposures in periods outside that window may
ias results toward the null and make comparison among stud-
es difﬁcult. Regardless of what exposure time period is chosen,
he time interval between maternal immunization and diagnosis
f a congenital anomaly should be recorded to provide additional
nformation when evaluating the association between maternal
accination and congenital anomalies. The clinical manifestations
nd time-lines are dependent on the congenital anomaly being
valuated.
We postulate that a deﬁnition designed to be a suitable tool for
esting causal relationships requires ascertainment of the outcome
e.g., congenital anomalies) independent from the exposure (e.g.,
mmunisations). Therefore, to avoid selection bias, a restrictive
ime interval from maternal immunization to diagnosis of congen-
tal anomalies should not be an integral part of such a deﬁnition.
nstead, where feasible, details of this interval should be assessed
nd reported as described in the data collection guidelines.
Further, congenital anomalies often occur outside the controlled
etting of a clinical trial or hospital. In some settings it may  be
mpossible to obtain a clear gestational age at vaccination, par-
icularly in less developed or rural settings. In order to avoid
electing against such cases, the Brighton Collaboration case deﬁ-
ition avoids setting arbitrary time frames.
It is important to differentiate congenital anomalies with
ell-documented causes from congenital anomalies without clear
tiologies. Therefore, while the case deﬁnition includes congeni-
al anomalies which are part of well-known syndromes associated
ith maternal medications (e.g., anti-epileptic medications), tox-
ns (e.g., alcohol), and infections (e.g., rubella), we recommend
ltering the analysis plan if a study includes these cases [66,68].
or example, a congenital heart defect associated with fetal alcohol
yndrome would be included in a study of congenital anoma-
ies following immunization. However, the analysis plan would
ifferentiate between this congenital anomaly and others which
re not due to a known alternative etiology. Similarly, congenital
nomalies associated with prematurity will be included during data
ollection, even if the congenital anomaly is clearly attributable to
rematurity, and then accounted for during data analysis.
.3.2. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case deﬁnition is
ccompanied by guidelines which are structured according to the
teps of conducting a clinical trial, i.e. data collection, analysis and
resentation. Neither case deﬁnition nor guidelines are intended to
uide or establish criteria for management of ill infants, children,
M. DeSilva et al. / Vacr adults. Both were developed to improve data comparability. As
any studies of congenital anomalies following immunization will
ccur as part of post-marketing surveillance, it is our hope that
he following deﬁnitions can also be applied in observational stud-
es.1.4. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
lines, review of the deﬁnition with its guidelines is planned on a
regular basis (i.e. every three to ﬁve years) or more often if needed.
2. Case deﬁnition of major congenital anomalies
2.1. For all levels of diagnostic certainty
A major congenital anomaly is a structural or functional defect
with the following three characteristics:
1. Of prenatal origin
2. Present at the time of live birth or fetal demise, or in utero
3. Affecting (or has the propensity to affect) the health, survival, or
physical or cognitive functioning of the individual
The majority of structural congenital anomalies are diagnosed
before 2 years of age, usually within the ﬁrst 6 months of life, and
are deﬁned by:
Major External Structural Defects
Level 1 of diagnostic certainty for major external structural
defects*
• Alterations in external anatomy visible at the time of live birth
and persistent beyond the immediate peripartum period unless
surgically repaired
OR
• Alterations in external anatomy visible in a stillbirth or in
the products of conception of a spontaneous or therapeutic
abortion
AND
• Conﬁrmed by documentation of a diagnosis made by a clinician
experienced in diagnosing congenital anomalies and with the
highest level of morphology training for the speciﬁc setting**
Level 2 of diagnostic certainty for major external structural
defects
• Alterations in external anatomy visible at the time of live birth
and persistent beyond the immediate peripartum period unless
surgically repaired
OR
• Alterations in external anatomy visible in a stillbirth or in the
products of conception of a spontaneous or therapeutic abortion
AND
• Conﬁrmed by documentation of a diagnosis made by a clinician
with some experience diagnosing congenital anomalies***
Level 3 of diagnostic certainty for major external structural
defects
• Alterations in external anatomy visible at the time of live birth
and persistent beyond the immediate peripartum period unless
surgically repaired
OR
• Alterations in external anatomy visible in a stillbirth or in
the products of conception of a spontaneous or therapeutic
abortion****
AND
• Conﬁrmed by documentation of a diagnosis made by a trained
maternal or child health care provider with at least minimal
experience diagnosing congenital anomalies
 (2016) 4 6015–6026OR
• For live births, conﬁrmed using individual (ICD-9/ICD-10) codes
or as part of an ICD-9/ICD-10 code based algorithm, where the
outcome (individual code or algorithm) has been validated*****
• Conﬁrmed by deﬁnitive diagnostic study**
cine 3Level 4 of diagnostic certainty (insufﬁcient evidence to con-
ﬁrm) for major external structural defects
• Alterations in external anatomy visible at the time of
live birth and persistent beyond the immediate peripartum
period unless surgically repaired
OR
• Alterations in external anatomy visible in a stillbirth or in the
products of conception of a spontaneous or therapeutic abortion
AND
• Conﬁrmed by medical record review******
OR
• Conﬁrmed in claims data (ICD-9/ICD-10 diagnoses)******
*Please see Appendix A for a list of major external structural
defects
**In high resource settings with access to subspecialists, such
as the United States, these clinicians could be geneticists,
neonatologists, pathologists, or other relevant subspecialists
while in low and middle income countries, diagnosis by a gen-
eral physician trained in morphology could be sufﬁcient
***In high resource settings, such as the United States, these
clinicians might include physicians, nurse practitioners, or
physician’s assistants trained in pediatrics, obstetrics, or fam-
ily medicine while in low and middle income countries,
diagnosis by a general physician trained in morphology could
be sufﬁcient
****In cases of therapeutic or spontaneous abortion, if prod-
ucts of conception cannot be used for detailed morphologic
exam, detection of an external structural defect on prenatal
ultrasound could be classiﬁed as Level 3
*****Validation should be conducted in the same data source,
with clinical diagnosis or chart review as the gold standard and
a positive predictive value of ≥80%
******Where there is insufﬁcient detail in the chart or lack of
validation in outcome to meet criteria for Level 3
Major Internal Structural Defects
Level 1 of diagnostic certainty for major internal structural
defects*
• Alterations in internal anatomy present at the time of
live birth** and persistent beyond the immediate peripartum
period unless surgically repaired
AND
• Conﬁrmed by deﬁnitive imaging study*** or intraoperative
diagnosis
OR
• Alterations in internal anatomy detected during autopsy for
a stillbirth, spontaneous or therapeutic abortion conﬁrmed by
documentation by a pathologist or other relevant subspecialist
Level 2 of diagnostic certainty for major internal structural
defects
• Alterations in internal anatomy present at the time of
live birth** and persistent beyond the immediate peripartum
period unless surgically repaired
AND
• Conﬁrmed by documentation of a diagnosis made by a clinician
experienced in diagnosing congenital anomalies and with the
highest level of morphology training for the speciﬁc setting****
without deﬁnitive imaging or intraoperative evaluation
OR
• For stillbirth, spontaneous or therapeutic abortion, internal
structural defect is visible by ultrasound or other imaging
modality prenatally
Level 3 of diagnostic certainty for major internal structural
defects
M. DeSilva et al. / Vac• Alterations in internal anatomy present at the time of
live birth** and persistent beyond the immediate peripartum
period unless surgically repairedAND
• Conﬁrmed by documentation of a diagnosis made by a clinician
with some experience diagnosing congenital anomalies*****
OR
• Conﬁrmed using individual (ICD-9/ICD-10) codes or as part
of an ICD-9/ICD-10 code based algorithm, where the outcome
(individual code or algorithm) has been validated******
Level 4 of diagnostic certainty (insufﬁcient evidence to con-
ﬁrm) for major internal structural defects
• Alterations in internal anatomy present at the time of
live birth** and persistent beyond the immediate peripartum
period unless surgically repaired
OR
• Alterations in internal anatomy present at time of stillbirth,
spontaneous abortion, or induced abortion
AND
• Conﬁrmed through medical record review, with the medical
record demonstrating that the anomaly was present at the time
of live birth or time of fetal demise, and that the anomaly was
diagnosed by a trained maternal or child health care provider
with minimal experience diagnosing congenital anomalies
OR
• Conﬁrmed by claims data (ICD-9/ICD-10 diagnoses)*******
*Please see Appendix B for a list of major internal structural
defects
**For pyloric stenosis, the propensity to develop this condi-
tion is present at birth
***Type of deﬁnitive imaging study depends on the speciﬁc
anomaly
****In high resource settings with access to subspecialists,
such as the United States, these clinicians could be geneticists,
neonatologists, pathologists, or other relevant subspecialists
while in low and middle income countries, diagnosis by a
general physician trained in morphology could be sufﬁcient
*****In high resource settings such as the United States, these
clinicians might include physicians, nurse practitioners, or
physician’s assistants trained in pediatrics, obstetrics, or fam-
ily medicine while in low and middle income countries,
diagnosis by a general physician trained in morphology could
be sufﬁcient
******Validation should be conducted in the same data source,
with clinical diagnosis or chart review as the gold standard
and a positive predictive value of ≥80%
*******Where there is insufﬁcient detail in the chart or lack of
validation in outcome to meet criteria for Level 3
Additionally, many functional congenital anomalies are diag-
nosed before 2 years of age, usually within the ﬁrst 6 months
of life, but some functional defects may  not be diagnosed until
later in life and are deﬁned by:
Functional Defects
Level 1 of diagnostic certainty for major functional defects*
• For live births, alterations in functioning of one or more organs
or body parts not due to a structural defect, present at the
time of birth (or propensity to develop alteration present at
live birth), and persistent beyond the immediate peripartum
period, unless treated through gene therapy or stem cell trans-
plantation
OR
• For stillbirths, spontaneous or therapeutic abortions, alter-
ations in functioning of one or more organs or body parts, not
due to a structural defect
AND
 (2016) 4 6015–6026 6021Level 2 of diagnostic certainty for major functional defects*
• For live births, alterations in functioning of one or more organs
or body parts not due to a structural defect, present at live
for the subject, as applicable.
(4) Relation to the patient (e.g., immunizer [clinician, nurse], family
member [indicate relationship], other).
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birth (or propensity to develop alteration present at live birth),
and persistent beyond the immediate peripartum period, unless
treated through gene therapy or stem cell transplantation
OR
• For stillbirths, spontaneous or therapeutic abortions, alter-
ations in functioning of one or more organs or body parts, not
due to a structural defect
AND
• Conﬁrmed by documentation of a diagnosis made by a clinician
experienced in diagnosing congenital anomalies and with the
highest level of training in the diagnosis of functional defects
for the speciﬁc setting***
Level 3 of diagnostic certainty for major functional defects*
• For live births, alterations in functioning of one or more organs
or body parts not due to a structural defect, present at live
birth (or propensity to develop alteration present at live birth),
and persistent beyond the immediate peripartum period, unless
treated through gene therapy or stem cell transplantation
OR
• For stillbirths, spontaneous or therapeutic abortions, alter-
ations in functioning of one or more organs or body parts, not
due to a structural defect
AND
• Conﬁrmed by documentation of a diagnosis made by a clinician
with some experience diagnosing functional defects****
OR
• Conﬁrmed using individual (ICD-9/ICD-10) codes or as part
of an ICD-9/ICD-10 code based algorithm, where the outcome
(individual code or algorithm) has been validated*****
Level 4 of diagnostic certainty (insufﬁcient evidence to con-
ﬁrm) for major functional defects*
• For live births, alterations in functioning of one or more organs
or body parts not due to a structural defect, present at the time
of live birth (or propensity to develop alteration present at live
birth), and persistent beyond the immediate peripartum period,
unless treated through gene therapy or stem cell transplanta-
tion
OR
• For stillbirths, spontaneous or therapeutic abortions, alter-
ations in functioning of one or more organs or body parts, not
due to a structural defect
AND
• Conﬁrmed through medical record review, with the medi-
cal record demonstrating that the anomaly was present at
the time of live birth or time of fetal demise, and that the
anomaly was diagnosed by a trained maternal or child health
care provider who is not a qualiﬁed geneticist, neonatologist,
pathologist, subspecialist, pediatrician, obstetrician, or family
medicine practitioner
OR
• Conﬁrmed by claims data (ICD-9/ICD-10 diagnoses)******
*Please see Appendix C for a list of major functional defects
**Type of conﬁrmatory study (e.g., chromosome analysis,
FISH) depends on the speciﬁc anomaly
***In high resource settings with access to subspecialists, such
as the United States, these clinicians could be geneticists,
neonatologists, pathologists, or other relevant subspecial-
ists while in low and middle income countries, diagnosis
by a general physician trained in morphology could be
sufﬁcient
****In high resource settings, such as the United States, these
clinicians might include physicians, nurse practitioners, or
physician’s assistants trained in pediatrics, obstetrics, or fam-
M. DeSilva et al. / Vac022ily medicine while in low and middle income countries,
diagnosis by a general physician with some training in diag-
nosis of functional defects could be sufﬁcient*****Validation should be conducted in the same data source,
with clinical diagnosis or chart review as the gold standard
and a positive predictive value of ≥80%
******Where there is insufﬁcient detail in the chart or lack of
validation in outcome to meet criteria for Level 3
3. Guidelines for data collection, analysis and presentation
of congenital anomalies
It was the consensus of the Brighton Collaboration Congenital
Anomalies Working Group to recommend the following guidelines
to enable meaningful and standardized collection, analysis, and
presentation of information about congenital anomalies. However,
implementation of all guidelines might not be possible in all sett-
ings. The availability of information may  vary depending upon
resources, geographical region, and whether the source of informa-
tion is a prospective clinical trial, a post-marketing surveillance or
epidemiological study, or an individual report of congenital anoma-
lies. Also, as explained in more detail in the overview paper in
this volume, these guidelines have been developed by this working
group for guidance only, and are not to be considered a mandatory
requirement for data collection, analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following immunization to allow for
comparability of data, and are recommended as an addition to data
collected for the speciﬁc study question and setting. The guide-
lines are not intended to guide the primary reporting of congenital
anomalies to a surveillance system or study monitor. Investigators
developing a data collection tool based on these data collection
guidelines also need to refer to the criteria in the case deﬁnition,
which are not repeated in these guidelines.
Guidelines numbered below have been developed to address
data elements for the collection of adverse event information as
speciﬁed in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for Reg-
istration of Pharmaceuticals for Human Use [69] and the form
for reporting of drug adverse events by the Council for Interna-
tional Organizations of Medical Sciences [70]. These data elements
include an identiﬁable reporter and patient, one or more prior
maternal immunisations, and a detailed description of the adverse
event, in this case, of congenital anomalies following maternal
immunization. The additional guidelines have been developed as
guidance for the collection of additional information to allow for
a more comprehensive understanding of congenital anomalies fol-
lowing maternal immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting2 and/or
diagnosing the congenital anomaly(ies) as speciﬁed by country-
speciﬁc data protection law.
(3) Name and contact information of the investigator responsible
 (2016) 4 6015–60262 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.
3
3
a
(
(
(
3
a
s
(
3
f
(
(
(
(
(
3
(
ﬁve categories including the four levels of diagnostic cer-
tainty. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case def-
inition should be classiﬁed in the additional categories for
analysis.
3 The date and/or time of ﬁrst observation of the ﬁrst sign or symptom indicative
ccine 3.1.2. Vaccinee/control
.1.2.1. Demographics. For all cases and/or all study participants,
s appropriate, the following information should be recorded:
5) Case/study participant identiﬁers (e.g., ﬁrst name initial fol-
lowed by last name initial) or code (or in accordance with
country-speciﬁc data protection laws).
6) Date of birth, stillbirth, or spontaneous or therapeutic abortion,
if applicable estimated gestational age at time of fetal demise,
age of mother, age of infant or gestational age of fetus, race and
ethnicity of both infant and mother, and sex of fetus.
7) For infants: Gestational age and birth weight.
.1.2.2. Clinical and immunization history. For all cases and/or
ll study participants, as appropriate, the following information
hould be recorded:
(8) For the mother, pre-conception medical history, including
hospitalizations, underlying diseases/disorders, and medi-
cations as well as medical history during pregnancy such
as exposure to substances related to major congenital
anomalies, tobacco use, alcohol use, illicit drug use, pre-
immunization signs and symptoms including identiﬁcation
of indicators for, or the absence of, a history of allergy to
vaccines, vaccine components or medications. Speciﬁc focus
should be on maternal medical conditions associated with
increased risk for having an infant with a congenital anomaly
(e.g., diabetes).
(9) Also, for the mother, any medication history (other than treat-
ment for the event described) prior to, during, and after
immunization including prescription and non-prescription
medication with a speciﬁc focus on potentially teratogenic
medication exposures. Use of prenatal vitamins and folic acid
should also be noted.
10) Maternal immunization history (i.e. previous immunizations
and any adverse event following immunization (AEFI)), in
particular occurrence of a congenital anomaly in a prior preg-
nancy following previous maternal immunization.
.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:
11) Date and time of maternal immunization(s).
12) Description of vaccine(s) (name of vaccine, manufacturer,
lot number, dose (e.g., 0.25 mL,  0.5 mL,  etc.) and number
of dose if part of a series of immunisations against the
same disease). The composition and volume of the dilu-
ent used as well as information about whether the diluent
was from the same or a separate container should also be
recorded.
13) The anatomical sites (including left or right side) of all immu-
nisations (e.g., vaccine A in proximal left lateral thigh, vaccine
B in left deltoid).
14) Route and method of administration (e.g., intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
15) Needle length and gauge.
.1.4. The adverse event
M. DeSilva et al. / Va16) For all cases at any level of diagnostic certainty and for
reported events with insufﬁcient evidence, the criteria ful-
ﬁlled to meet the case deﬁnition should be recorded.
Speciﬁcally document:(17) Clinical description of signs and symptoms of one or more con-
genital anomalies, and if there was  medical conﬁrmation of the
event (e.g., patient seen by physician).
(18) Date/time of ﬁrst observation3 of congenital anomaly and
diagnostic conﬁrmation4 and ﬁnal outcome.5
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testing – relevant laboratory testing, imaging
results, surgical and pathologic reports.
(21) Treatment given for congenital anomaly(ies), especially
whether surgical intervention was required.
(22) Physical and developmental outcome5 at last observation for
living infants.
(23) Objective clinical evidence supporting classiﬁcation of the
congenital anomaly as “major,” varies depending on congeni-
tal anomaly evaluating.
(24) Exposures other than maternal immunization during preg-
nancy (e.g., maternal medications, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The duration of surveillance for congenital anomalies includes
any anomalies identiﬁed after the date of vaccination.
(26) The duration of follow-up reported during the surveillance
period should be predeﬁned likewise. Although most con-
genital anomalies will be clinically recognized in the ﬁrst 30
days of life, some may not be evident until 12–24 months or
later.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete the
information collected as outlined in data collection guidelines
1 to 24.
(29) Investigators of patients with congenital anomalies should
provide guidance to reporters to optimize the quality and
completeness of information provided.
(30) Reports of congenital anomalies should be collected through-
out the study period regardless of the time elapsed between
immunization and the adverse event. If this is not feasible due
to the study design, the study periods during which safety data
are being collected should be clearly deﬁned.
3.2. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on congenital anomalies to allow for comparability of
data, and are recommended as an addition to data analyzed for the
speciﬁc study question and setting.
(31) Reported events should be classiﬁed in one of the following
 (2016) 4 6015–6026 6023for  Congenital Anomalies can be used if date/time of onset is not known.
4 The date of diagnosis of an episode is the day post immunization when the event
met  the case deﬁnition at any level.
5 E.g., recovery to pre-immunization health status, spontaneous resolution, ther-
apeutic intervention, persistence of the event, sequelae, death.
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Event classiﬁcation in 5 categories6
Event meets case deﬁnition
Level 1: Criteria as speciﬁed in the Major Congenital Anomalies case
deﬁnition
Specify Major External Structural, Major Internal Structural or
Major Functional
Level 2: Criteria as speciﬁed in the Major Congenital Anomalies case
deﬁnition
Specify Major External Structural, Major Internal Structural or
Major Functional
Level 3: Criteria as speciﬁed in the Major Congenital Anomalies case
deﬁnition
Specify Major External Structural, Major Internal Structural or
Major Functional
Insufﬁcient Evidence to Conﬁrm case deﬁnition
Level 4: Criteria as speciﬁed in the Major Congenital Anomalies case
deﬁnition
Specify Major External Structural, Major Internal Structural or
Major Functional
Event does not meet case deﬁnition
Level 5: Not a major congenital anomaly
In addition, major congenital anomalies attributed to an alter-
ative cause (e.g., congenital CMV) should still be recorded and
dentiﬁed as likely attributable to a known cause.
32) The interval between maternal immunization and reported
congenital anomaly could be deﬁned as the date/time of
immunization (with regards to gestational age) to the
date/time of clinical recognition7 of the ﬁrst symptoms and/or
signs consistent with the deﬁnition. If few cases are reported,
the concrete time course could be analyzed for each; for a
large number of cases, data can be analyzed in the following
increments:
Time Interval
Days prior to mother’s last menstrual period
0 to <14 weeks gestational age (highest risk for congenital
anomaly)
14 to <20 weeks gestational age (lower risk for congenital
anomaly)
≥20 weeks gestation (unlikely to be in risk window for congenital
anomaly)
M. DeSilva et al. / Vac024Periods of infancy for age of clinical recognition of congenital
nomaly.
6 To determine the appropriate category, the user should ﬁrst establish, whether
 reported event meets the criteria for the lowest applicable level of diagnostic
ertainty, e.g., Level three. If the lowest applicable level of diagnostic certainty of
he deﬁnition is met, and there is evidence that the criteria of the next higher level
f  diagnostic certainty are met, the event should be classiﬁed in the next category.
his approach should be continued until the highest level of diagnostic certainty
or a given event could be determined. Major criteria can be used to satisfy the
equirement of minor criteria. If the lowest level of the case deﬁnition is not met, it
hould be ruled out that any of the higher levels of diagnostic certainty are met  and
he event should be classiﬁed in additional categories four or ﬁve.
7 The date and/or time of onset is deﬁned as the time post immunization, when the
rst  sign or symptom indicative for a Congenital Anomaly is clinically recognized.
his may  only be possible to determine in retrospect.Time period Days
Prenatal <Day 1 of life
Neonatala 1–27b
Early neonatala 1–6b
Late neonatala 7–27
Post neonatal 28–364
a Use either Neonatal or divide into early neonatal and late neonatal.
b Day 1 = ﬁrst 24 h of life.
(33) If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
(34) The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g., measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases are pre-
sented, the respective values or time course can be presented
individually.
(35) Data on congenital anomalies obtained from subjects receiv-
ing a vaccine should be compared with those obtained from
an appropriately selected and documented control group(s)
to assess background rates in non-exposed populations, and
should be analyzed by study arm and dose where possible, e.g.,
in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on congenital anomalies following
immunization to allow for comparability of data, and are recom-
mended as an addition to data presented for the speciﬁc study
question and setting. Additionally, it is recommended to refer
to existing general guidelines for the presentation and publi-
cation of randomized controlled trials, systematic reviews, and
meta-analyses of observational studies in epidemiology (e.g., state-
ments of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM), and of Meta-analysis Of Observational
Studies in Epidemiology (MOOSE), respectively).
(36) All reported events of congenital anomalies should be pre-
sented according to the categories listed in guideline 31.
(37) Data on possible congenital anomalies events should be pre-
sented in accordance with data collection guidelines 1–24 and
data analysis guidelines 31–34.
(38) Terms to describe congenital anomalies such as “low-grade”,
“mild”, “moderate”, “high”, “severe” or “signiﬁcant” are highly
subjective, prone to wide interpretation, and should be
avoided, unless clearly deﬁned.
(39) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomi-
nator data are usually not readily available, attempts should be
made to identify approximate denominators. The source of the
denominator data should be reported and calculations of estimates
be described (e.g., manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
 (2016) 6015–6026(40) The incidence of cases in the study population should be
presented and clearly identiﬁed as such in the text. It would
be useful to compare rates to background rates for these con-
ditions. Useful resources include: EUROCAT prevalence tables
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cine 34(http://www.eurocat-network.eu/accessprevalencedata/
prevalencetables). This allows that both exposed an
unexposed cohorts can be compared with an external
standard.
41) If the distribution of data is skewed, median and range are usu-
ally the more appropriate statistical descriptors than a mean.
However, the mean and standard deviation should also be
provided.
42) We  recommend the studies powered to evaluate compos-
ite congenital anomaly outcomes also publish, or make data
available that contains a description of individual anomalies.
This will potentially allow meta-analysis of more discrete out-
comes and help deﬁne the risk of less frequent anomalies.
43) Any publication of data on congenital anomalies should
include a detailed description of the methods used for data
collection and analysis as possible. It is essential to specify:
The study design;
The method, frequency and duration of monitoring for congenital
anomalies;
The trial proﬁle, indicating participant ﬂow during a study includ-
ing drop-outs and withdrawals to indicate the size and nature of
the respective groups under investigation;
The type of surveillance (e.g., passive or active surveillance);
The characteristics of the surveillance system (e.g., population
served, mode of report solicitation);
The search strategy in surveillance databases;
Comparison group(s), if used for analysis;
The instrument of data collection (e.g., standardized question-
naire, diary card, report form);
Whether the day of immunization was considered “day one” or
“day zero” in the analysis;
Whether the date of timing of ﬁrst observation relative to
vaccination7 and/or the date of ﬁrst observation3 and/or the date
of diagnosis4 was used for analysis; and
Use of this case deﬁnition for congenital anomalies, in the abstract
or methods section of a publication.8,9,10,1112
cknowledgements
The authors are grateful for the support and helpful
omments provided by the Brighton Collaboration (Jan Bon-
oeffer, Jorgen Bauwens) and the reference group (see https://
rightoncollaboration.org/public/what-we-do/setting-standards/
ase-deﬁnitions/groups.html for reviewers), as well as other
xperts consulted as part of the process. The authors are also grate-
ul to the Brighton Collaboration Secretariat and to the members
M. DeSilva et al. / Vacf the ISPE Special Interest Group in Vaccines (VAX SIG) for their
eview and constructive comments on this document. Finally, we
ould like to acknowledge the Global Alignment of Immunization
8 Use of this document should preferably be referenced by referring to the respec-
ive link on the Brighton Collaboration website (http://www.brightoncollaboration.
rg).
9 The end of an episode is deﬁned as the time the event no longer meets the case
eﬁnition at the lowest level of the deﬁnition.
10 An AEFI is deﬁned as serious by international standards if it meets one or
ore of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
equires inpatient hospitalization or results in prolongation of existing hospitaliza-
ion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
nomaly/birth defect, (6) is a medically important event or reaction.
11 If the evidence available for an event is insufﬁcient because information is miss-
ng, such an event should be categorized as “Reported Congenital Anomalies with
nsufﬁcient evidence to meet the case deﬁnition”.
12 An event does not meet the case deﬁnition if investigation reveals a negative
nding of a necessary criterion (necessary condition) for diagnosis. Such an event
hould be rejected and classiﬁed as “Not a case of Congenital Anomalies”.
[
[
[
[
[
[
[
[Safety Assessment in Pregnancy (GAIA) project, funded by the Bill
and Melinda Gates Foundation.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.03.
047.
References
[1] Khoury MJ.  Epidemiology of birth defects. Epidemiol Rev 1989;11:244–8.
[2] Naghavi M,  Wang H, Lozano R, Davis A, Liang X, Zhou M,  et al. Global, regional,
and national age-sex speciﬁc all-cause and cause-speciﬁc mortality for 240
causes of death, 1990–2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet 2015;385:117–71.
[3] Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM,  Moore CA.
Guidelines for case classiﬁcation for the National Birth Defects Prevention
Study. Birth Defects Res A Clin Mol  Teratol 2003;67:193–201.
[4] Wellesley D, Boyd P, Dolk H, Pattenden S. An aetiological classiﬁcation of birth
defects for epidemiological research. J Med  Genet 2005;42:54–7.
[5] Prevention and control of inﬂuenza with vaccines: recommendations of the
Advisory Committee on Immunization Practices (ACIP), 2011. MMWR  Morb
Mortal Wkly Rep 2011;60:1128–32.
[6] Vaccines against inﬂuenza WHO  position paper – November 2012. Wkly Epi-
demiol Rec 2012;87:461–76.
[7] Christian LM,  Iams JD, Porter K, Glaser R. Inﬂammatory responses to trivalent
inﬂuenza virus vaccine among pregnant women. Vaccine 2011;29:8982–7.
[8] Christian LM,  Porter K, Karlsson E, Schultz-Cherry S, Iams JD. Serum proinﬂam-
matory cytokine responses to inﬂuenza virus vaccine among women during
pregnancy versus non-pregnancy. Am J Reprod Immunol 2013;70:45–53.
[9] Chambers CD, Johnson D, Xu R, Luo Y, Louik C, Mitchell AA, et al. Risks and
safety of pandemic H1N1 inﬂuenza vaccine in pregnancy: birth defects, sponta-
neous abortion, preterm delivery, and small for gestational age infants. Vaccine
2013;31:5026–32.
10] Deinard AS, Ogburn P. A/NJ/8/76 inﬂuenza vaccination program: effects
on  maternal health and pregnancy outcome. Am J Obstet Gynecol
1981;140:240–5.
11] Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, et al. Safety
of  MF59-adjuvanted A/H1N1 inﬂuenza vaccine in pregnancy: a comparative
cohort study. Am J Obstet Gynecol 2012;207, 177 e1–8.
12] Kallen B, Olausson PO. Vaccination against H1N1 inﬂuenza with Pandem-
rix((R)) during pregnancy and delivery outcome: a Swedish register study. BJOG
2012;119:1583–90.
13] Launay O, Krivine A, Charlier C, Truster V, Tsatsaris V, Lepercq J, et al. Low rate
of  pandemic A/H1N1 2009 inﬂuenza infection and lack of severe complica-
tion of vaccination in pregnant women: a prospective cohort study. PLoS ONE
2012;7:e52303.
14] Louik C, Ahrens K, Kerr S, Pyo J, Chambers C, Jones KL, et al. Risks and safety of
pandemic H1N1 inﬂuenza vaccine in pregnancy: exposure prevalence, preterm
delivery, and speciﬁc birth defects. Vaccine 2013;31:5033–40.
15] Mackenzie IS, MacDonald TM,  Shakir S, Dryburgh M, Mantay BJ, McDonnell P,
et al. Inﬂuenza H1N1 (swine ﬂu) vaccination: a safety surveillance feasibility
study using self-reporting of serious adverse events and pregnancy outcomes.
Br  J Clin Pharmacol 2012;73:801–11.
16] Oppermann M,  Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allig-
nol A, Meister R, et al. A(H1N1)v2009: a controlled observational prospective
cohort study on vaccine safety in pregnancy. Vaccine 2012;30:4445–52.
17] Pasternak B, Svanstrom H, Molgaard-Nielsen D, Krause TG, Emborg HD, Melbye
M,  et al. Risk of adverse fetal outcomes following administration of a pandemic
inﬂuenza A(H1N1) vaccine during pregnancy. JAMA 2012;308:165–74.
18] Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, et al.
Inﬂuenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse
perinatal outcomes: multicentre study. BMJ  2013;346:f393.
19] Shefﬁeld JS, Greer LG, Rogers VL, Roberts SW,  Lytle H, McIntire DD, et al. Effect
of  inﬂuenza vaccination in the ﬁrst trimester of pregnancy. Obstet Gynecol
2012;120:532–7.
20] Munoz FM,  Englund JA, Cheesman CC, Maccato ML, Pinell PM,  Nahm MH,
et al. Maternal immunization with pneumococcal polysaccharide vaccine in
the third trimester of gestation. Vaccine 2001;20:826–37.
21] McMillan M,  Porritt K, Kralik D, Costi L, Marshall H. Inﬂuenza vaccination dur-
ing  pregnancy: a systematic review of fetal death, spontaneous abortion, and
congenital malformation safety outcomes. Vaccine 2015;33:2108–17.
22] Demicheli V, Jefferson T, Al-Ansary Lubna A, Ferroni E, Rivetti A, Di Pietrantonj
C.  Vaccines for preventing inﬂuenza in healthy adults. Cochrane database of
 (2016) 6015–6026 6025systematic reviews. John Wiley & Sons, Ltd.; 2014.
23] Fabiani M,  Bella A, Rota MC,  Clagnan E, Gallo T, D’Amato M,  et al. A/H1N1 pan-
demic inﬂuenza vaccination: a retrospective evaluation of adverse maternal,
fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine
2015;33:2240–7.
[[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
cine 346  
24] Trotta F, Da Cas R, Spila Alegiani S, Gramegna M,  Venegoni M, Zocchetti C, et al.
Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort
study. BMJ  2014;348:g3361.
25] Huang WT,  Tang FW,  Yang SE, Chih YC, Chuang JH. Safety of inactiv-
ated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a
population-based study in Taiwan. Vaccine 2014;32:6463–8.
26] Pertussis vaccines: WHO  position paper – September 2015. Wkly Epidemiol
Rec  2015;90:433–58.
27] Updated recommendations for use of tetanus toxoid, reduced diphtheria tox-
oid,  and acellular pertussis vaccine (Tdap) in pregnant women—Advisory
Committee on Immunization Practices (ACIP) 2012. MMWR  Morb Mortal Wkly
Rep  2013;62:131–5.
28] Munoz FM,  Bond NH, Maccato M,  Pinell P, Hammill HA, Swamy GK, et al.
Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap)
immunization during pregnancy in mothers and infants: a randomized clinical
trial. JAMA 2014;311:1760–9.
29] Shakib JH, Korgenski K, Sheng X, Varner MW,  Pavia AT, Byington CL. Tetanus,
diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant
health outcomes. J Pediatr 2013;163, 1422–6 e1–4.
30] Morgan JL, Baggari SR, McIntire DD, Shefﬁeld JS. Pregnancy outcomes after
antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet
Gynecol 2015;125:1433–8.
31] Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, et al.
Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acel-
lular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012;207, 59
e1–7.
32] Tetanus vaccine. Wkly Epidemiol Rec 2006;81:198–208.
33] Heinonen O, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Publishing
Sciences Group; 1977.
34] Czeizel AE, Rockenbauer M.  Tetanus toxoid and congenital abnormalities. Int J
Gynaecol Obstet 1999;64:253–8.
35] Silveira CM, Caceres VM,  Dutra MG,  Lopes-Camelo J, Castilla EE. Safety of
tetanus toxoid in pregnant women: a hospital-based case-control study of
congenital anomalies. Bull World Health Organ 1995;73:605–8.
36] TORCH syndrome and TORCH screening. Lancet 1990;335:1559–61.
37] Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynek H,
et  al. Safety of immunization during pregnancy: a review of the evidence of
selected inactivated and live attenuated vaccines. Vaccine 2014;32:7057–64.
38] Bar-Oz B, Levichek Z, Moretti ME,  Mah  C, Andreou S, Koren G. Pregnancy out-
come following rubella vaccination: a prospective controlled study. Am J Med
Genet Part A 2004;130A:52–4.
39] da Silva e Sa GR, Camacho LA, Stavola MS,  Lemos XR, Basilio de Oliveira CA,
Siqueira MM.  Pregnancy outcomes following rubella vaccination: a prospec-
tive study in the state of Rio de Janeiro Brazil, 2001–2002. J Infect Dis
2011;204(Suppl. 2):S722–8.
40] Badilla X, Morice A, Avila-Aguero ML,  Saenz E, Cerda I, Reef S, et al. Fetal
risk  associated with rubella vaccination during pregnancy. Pediatr Infect Dis
J  2007;26:830–5.
41] Minussi L, Mohrdieck R, Bercini M,  Ranieri T, Sanseverino MT,  Momino W,
et  al. Prospective evaluation of pregnant women vaccinated against rubella
in  southern Brazil. Reprod Toxicol 2008;25:120–3.
42] Pardon F, Vilarino M,  Barbero P, Garcia G, Outon E, Gil C, et al. Rubella vac-
cination of unknowingly pregnant women during 2006 mass campaign in
Argentina. J Infect Dis 2011;204(Suppl. 2):S745–7.
43] Soares RC, Siqueira MM,  Toscano CM,  Maia Mde L, Flannery B, Sato HK, et al.
Follow-up study of unknowingly pregnant women  vaccinated against rubella
in  Brazil, 2001–2002. J Infect Dis 2011;204(Suppl. 2):S729–36.
44] Hamkar R, Jalilvand S, Abdolbaghi MH,  Esteghamati AR, Hagh-Goo A, Jelyani KN,
et  al. Inadvertent rubella vaccination of pregnant women: evaluation of possi-
ble transplacental infection with rubella vaccine. Vaccine 2006;24:3558–63.
45] Castillo-Solorzano C, Reef SE, Morice A, Vascones N, Chevez AE, Castalia-Soares
R,  et al. Rubella vaccination of unknowingly pregnant women  during mass cam-
paigns for rubella and congenital rubella syndrome elimination, the Americas
2001–2008. J Infect Dis 2011;204(Suppl. 2):S713–7.
46] Sukumaran L, McNeil MM,  Moro PL, Lewis PW,  Winiecki SK, Shimabukuro
M. DeSilva et al. / Vac026TT. Adverse events following measles, mumps, and rubella vaccine in adults
reported to the vaccine adverse event reporting system (VAERS), 2003–2013.
Clin  Infect Dis 2015;60:e58–65.
47] Burton AE, Robinson ET, Harper WF,  Bell EJ, Boyd JF. Fetal damage after acciden-
tal  polio vaccination of an immune mother. J R Coll Gen Pract 1984;34:390–4.
[
[
[48] Harjulehto-Mervaala T, Aro T, Hiilesmaa VK, Hovi T, Saxen H, Saxen L. Oral
polio vaccination during pregnancy: lack of impact on fetal development and
perinatal outcome. Clin Infect Dis 1994;18:414–20.
49] Suzano CE, Amaral E, Sato HK, Papaiordanou PM,  Campinas Group on Yellow
Fever Immunization during Pregnancy. The effects of yellow fever immuniza-
tion (17DD) inadvertently used in early pregnancy during a mass campaign in
Brazil. Vaccine 2006;24:1421–6.
50] Cavalcanti DP, Salomao MA,  Lopez-Camelo J, Pessoto MA,  Campinas Group of
Yellow Fever Immunization during Pregnancy. Early exposure to yellow fever
vaccine during pregnancy. Trop Med  Int Health 2007;12:833–7.
51] Wilson E, Goss MA, Marin M,  Shields KE, Seward JF, Rasmussen SA, et al. Vari-
cella vaccine exposure during pregnancy: data from 10 years of the pregnancy
registry. J Infect Dis 2008;197(Suppl. 2):S178–84.
52] Angelo MG,  David MP,  Zima J, Baril L, Dubin G, Arellano F, et al. Pooled analysis
of large and long-term safety data from the human papillomavirus-16/18-
AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug
Saf  2014;23:466–79.
53] Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Preg-
nancy and infant outcomes in the clinical trials of a human papillomavirus
type 6/11/16/18 vaccine: a combined analysis of ﬁve randomized controlled
trials. Obstet Gynecol 2009;114:1179–88.
54] Dana A, Buchanan KM,  Goss MA, Seminack MM,  Shields KE, Korn S, et al. Preg-
nancy outcomes from the pregnancy registry of a human papillomavirus type
6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170–8.
55] Goss MA,  Lievano F, Buchanan KM,  Seminack MM,  Cunningham ML,  Dana
A.  Final report on exposure during pregnancy from a pregnancy reg-
istry for quadrivalent human papillomavirus vaccine. Vaccine 2015;33:
3422–8.
56] Angelo MG,  Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure
safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vac-
cine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014;23:
456–65.
57] Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of quadri-
valent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events
among non-manufacturer reports in the Vaccine Adverse Event Reporting Sys-
tem,  2006–2013. Vaccine 2015;33:519–22.
58] Nakalembe M,  Mirembe FM,  Banura C. Vaccines against human papillomavirus
in low and middle income countries: a review of safety, immunogenicity and
efﬁcacy. Infect Agents Cancer 2015;10:17.
59] Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao  C, Mehlsen J, et al. A 9-valent
HPV  vaccine against infection and intraepithelial neoplasia in women. N Engl J
Med  2015;372:711–23.
60] Makris MC,  Polyzos KA, Mavros MN,  Athanasiou S, Rafailidis PI, Falagas
ME.  Safety of hepatitis B, pneumococcal polysaccharide and meningococ-
cal  polysaccharide vaccines in pregnancy: a systematic review. Drug Saf
2012;35:1–14.
61] Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-
protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event
Reporting System. Am J Obstet Gynecol 2013;208, 478 e1–6.
62] Ouandaogo CR, Yameogo TM,  Diomande FV, Sawadogo C, Ouedraogo B,
Ouedraogo-Traore R, et al. Adverse events following immunization during mass
vaccination campaigns at ﬁrst introduction of a meningococcal A conjugate
vaccine in Burkina Faso, 2010. Vaccine 2012;30(Suppl. 2):B46–51.
63] Update on overall prevalence of major birth defects—Atlanta, Georgia,
1978–2005. MMWR  Morb Mortal Wkly Rep 2008;57:1–5.
64] Population-based Birth Defects Surveillance data from selected states,
2002–2006. Birth Defects Res A Clin Mol  Teratol 2009;85:939–1055.
65] Kohl KS, Gidudu J, Bonhoeffer J, Braun MM,  Buettcher M,  Chen RT, et al. The
development of standardized case deﬁnitions and guidelines for adverse events
following immunization. Vaccine 2007;25:5671–4.
66] Obican S, Scialli AR. Teratogenic exposures. Am J Med  Genet Part C: Semin Med
Genet 2011;157C:150–69.
67] Shiota K. Variability in human embryonic development and its implications for
the susceptibility to environmental teratogenesis. Birth Defects Res A Clin Mol
Teratol 2009;85:661–6.
 (2016) 6015–602668] Rasmussen SA. Human teratogens update 2011: can we ensure safety during
pregnancy? Birth Defects Res A Clin Mol  Teratol 2012;94:123–8.
69] International Conference on Harmonization of Technical Requirements for Reg-
istration of Pharmaceuticals for Human Use.
70] Council for International Organizations of Medical Sciences.
